

Let's Talk:

From Dialogue to Decision-Making in HR+/HER2- Metastatic Breast Cancer With CDK4/6 Inhibitors



THURSDAY, 15 MAY 2025 | 12:45–13:45 CEST | HYBRID

**International Congress Center of the Munich Messe
Munich, Germany | Room 5**

OVERVIEW

During this engaging symposium, Drs Brufsky, Thill, and Biganzoli will review the latest clinical data on CDK4/6 inhibitors and discuss how to integrate clinical trial data and real-world evidence for individualised care in HR+/HER2- metastatic breast cancer (MBC). Through case-based discussions, the distinguished faculty will dive into current practice and shared decision-making for improved outcomes in patients with HR+/HER2- MBC. During the expert panel discussion, the engaging on-stage conversation will extend to participants with an interactive Q&A session.

AGENDA

- 12:45–12:50** **Welcome and Introduction**
Adam Brufsky, MD, PhD
- 12:50–13:00** **The Voice That Matters: Fostering Patient-Centred Care in HR+/HER2- Metastatic Breast Cancer**
Laura Biganzoli, MD
- 13:00–13:30** **How I Treat: Practice Insight Discussions for Individualised Care in 1L HR+/HER2- Metastatic Breast Cancer**
Adam Brufsky, MD, PhD
- 13:30–13:40** **Rapid Fire Panel Discussion and Audience Q&A**
All faculty
- 13:40–13:45** **Closing Remarks**
Adam Brufsky, MD, PhD

FACULTY



Adam Brufsky, MD, PhD
University of Pittsburgh
School of Medicine
Pittsburgh, Pennsylvania, United States



Laura Biganzoli, MD
Hospital of Prato
Azienda USL Toscana Centro
Prato, Italy



Marc Thill, MD, PhD
Agaplesion Markus
Krankenhaus
Frankfurt, Germany

- CDK4/6, cyclin-dependent kinase 4 and 6
- HR+, hormone receptor positive
- HER2-, human epidermal growth factor receptor 2 negative
- 1L, first line
- MBC, metastatic breast cancer